In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Beyondspring Inc (NASDAQ: BYSI), with a price target of $48. The company’s shares closed yesterday at $22.90, close to its 52-week low of $19.55.
McCarthy commented:
“BeyondSpring is moving closer to a pivotal data point for lead asset Plinabulin in 4Q that could stir up what’s already been an active neutropenia space.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 11.6% and a 42.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Beyondspring Inc has an analyst consensus of Moderate Buy, with a price target consensus of $54.
See today’s analyst top recommended stocks >>
The company has a one-year high of $42.49 and a one-year low of $19.55. Currently, Beyondspring Inc has an average volume of 7,734.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.
